Testing for tumour markers should only be performed if it results in a better patient outcome, increased quality of life or reduced overall cost of care. Ideally, the clinical value of a tumour marker should be validated in a large prospective study or a metaanalysis of small-scale retrospective/prospective studies (i.e. a level 1 evidence study) prior to routine use. Markers that have been validated in such a level 1 evidence study include carcinoembryonic antigen in the surveillance of patients with diagnosed colorectal cancer, alphafetoprotein, human chorionic gonadotrophin and lactate dehydrogenase for evaluating prognosis in patients non-seminomatous germ cell tumours, CA 125 for monitoring therapy in patients with ovarian cancer, oestrogen receptors for predicting response to hormone therapy in breast cancer, HER-2 for predicting response to trastuzumab in patients with advanced breast cancer and urokinase plasminogen activator/plasminogen activator inhibitor type 1 for determining prognosis in breast cancer. Although currently in widespread use, the value of prostate-specific antigen in screening for prostate cancer has yet to be validated in a large prospective randomized trial.
Introduction
Tumour markers are potentially useful in screening for early malignancy, aiding diagnosis, assessing prognosis, determining in advance the likely response to therapy and monitoring patients with diagnosed disease. 1 According to Hayes et al., 2 the use of a tumour marker should result in a more favourable clinical outcome (e.g. better disease-free or overall survival, enhanced quality of life or decreased costs of care) than if the marker was not used. Over the last 30 years, many new tumour markers have entered routine clinical use (see Table 1 ). The introduction of these markers was poorly controlled with no clear guidelines for their clinical utility. Furthermore, at the time of their introduction, there was little evidence that the measurement of these markers enhanced patient outcome. Subsequent studies, however, have shown that measurement of certain cancer markers can clearly result in improved patient management in de¢ned clinical situations.
The aim of this article is to review the evidence for the clinical utility of a number of markers currently in widespread use. For this article, evidence is de¢ned as clinical validation in either a large randomized prospective trial in which evaluation of the marker is the primary objective of the study, or in a metaanalysis/pooled analysis of small-scale prospective or retrospective trials (i.e. a level 1 evidence study). 2 The markers to be discussed include carcinoembryonic antigen (CEA), alphafetoprotein (AFP), human chorionic gonadotrophin (hCG), prostate-speci¢c antigen (PSA), CA 125, CA 15-3, oestrogen receptor (ER), HER-2, urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1).
CEA in surveillance of patients with diagnosed colorectal cancer
In 1981, a National Institute of Health Consensus Conference concluded that monitoring with CEA was the best available non-invasive technique for the detection of recurrences in patients with a previous diagnosis of colorectal cancer (CRCA). 3 Consequently, CEA began to be widely used in the follow-up of patients after curative resection for CRCA. For this purpose, serial CEA determination has been shown to detect recurrent disease with a sensitivity of approximately 80% and a speci¢city of approximately 70%. It also provides a median lead-time of approximately 5 months. 4 Furthermore, CEA is the most frequent 
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indicator of recurrent CRCA and is currently the most cost-e¡ective test for detecting potentially curative recurrent disease. 4 As regards the site of recurrence, CEA is most sensitive for detecting liver metastasis and least sensitive for detecting loco-regional disease. 4 A key question is whether the information provided by CEA is clinically useful^that is, if it enhances patient outcome, leads to a better quality of life or results in reduced overall cost of care. In recent years, at least three di¡erent meta-analyses have compared outcome following intensive versus control follow-up in patients with diagnosed CRCA. In the ¢rst, Bruinvels et al. 5 searched the literature published between 1986 and1991and identi¢ed seven non-randomized studies (n ¼ 3282) addressing this issue. The authors concluded that patients with intensive monitoring had a 9% better 5-year survival rate than those with minimal or no follow-up, only when CEA was included in the surveillance.
In a more recent meta-analysis, Rosen et al. 6 carried out a similar review of the literature but included publications up to 1996. Again, the aim of this study was to compare outcome in patients with intensive follow-up versus those with no follow-up. Intensive follow-up in this study was de¢ned as:
. At least history, physical examination and serial CEA assays . The interval for these follow-up periods was at least three times per year for the ¢rst 2 years . Mean follow-up after initial resection was at least 2 years.
The control group had no routine follow-up, with physicians only responding to changes in symptoms. From the literature review, two randomized and three comparative cohort studies, comprising 2005 patients, met the above criteria. Following evaluation in a meta-analysis the following conclusions emerged:
. The cumulative 5-year survival was 1.16 times higher in the intensively followed-up patients than in the controls (P ¼ 0.003) . More than twice as many curative re-resections were performed for recurrent cancer in the group with intensive follow-up than in the controls (P ¼ 0.0001) . Patients with intensive follow-up had a 3.6 times higher survival rate than the control group (P ¼ 0.0004).
In a third meta-analysis, Renehan et al. 7 identi¢ed ¢ve published randomised controlled trials (n ¼1342) that compared outcome following intensive versus control follow-up. Intensive follow-up was found to be associated with a signi¢cant reduction in all cause mortality (combined risk ratio 0.81, P ¼ 0.007). The reduced mortality was most pronounced in the four trials that used computed tomography (CT) and frequent assay of CEA. Furthermore, intensive followup was associated with signi¢cant earlier detection of all recurrences and an increased detection rate for isolated local recurrences.
Collectively, these meta-analyses show that the use of an intensive follow-up regime that includes regular CEA determinations results in a modest improvement in outcome for patients with CRCA. Since CEA is most useful in detecting liver metastasis and because of the relative success of surgery in treating liver metastasis from CRCA, an American Society of Clinical Oncology (ASCO) expert panel recommended that patients with both Dukes' B (Stage II) and C (Stage III) disease who may be candidates for liver resection should be followed-up with regular CEA determinations for at least 2 years. 8 A similar recommendation was recently published by the European Group on Tumour Markers (EGTM). 9 AFP, hCG and LDH in management of patients with germ cell tumours Using pooled data from more than 5000 patients, the International Germ Cell Cancer Collaborative Group reported that pre-treatment serum levels of AFP, hCG and LDH were independent prognostic factors for patients with metastatic non-seminomatous germ cell tumours (NSGCT). 10 Combining pre-treatment levels of these markers with speci¢c clinical parameters (location of the primary and metastatic sites) resulted in a new prognostic classi¢cation system for NSGCT. 10 In the late 1990s, AFP, hCG and LDH became the ¢rst tumour markers to be incorporated into both the American Joint Committee on Cancer and the Union Internationale Contre le Cancer (UICC) staging system for NSGCT. 11 Use of these markers for either staging or evaluation of prognosis in patients with NSGCT is now recommended by multiple Expert Panels, including the EGTM, European Society of Medical Oncology (ESMO), European Association of Urologists (EAU) and the National Academy of Clinical Biochemistry (NACB) in the USA. 12, 13 Evidence for the clinical use of tumour markers 371 Ann Clin Biochem 2004; 41: 370-377 Free PSA, complex PSA, HER-2
As well as determining prognosis, serial determinations of AFP and hCG are mandatory in the follow-up of patients with NSGCT. In postorchidectomy patients, rising AFP or hCG without radiological or clinical evidence of disease suggests active disease and may provide su⁄cient evidence to initiate treatment, provided likely causes of false positive marker levels can be eliminated. 14, 15 Although this statement was not based on results from a level 1 evidence study, most urological oncologists agree that serial determinations of AFP and hCG are highly informative in the follow-up of patients with NSGCTof the testis.
Segal et al. 16 performed a systematic review of the literature on surveillance programmes for early stage non-seminomatous testicular cancer with the aim of producing evidence-based practice. Following this literature review, the authors recommended that the follow-up of patients with NSGCT of the testis should include a physical examination, chest X-ray, measurement of AFP and beta hCG every month in the ¢rst year, every 2 months in the second year, every 3 months in the third year and every 6 months in the fourth and ¢fth years.
In a situation comparable to that with prognosis, follow-up of patients with NSGCT using both AFP and hCG is now recommended by multiple expert panels. 12, 13 As regards the type of hCG assay to be used for this purpose, the joint EGTM/NACB guidelines suggest use of an assay that detects the intact hCG molecule as well as its beta chain. 13 
PSA in screening for prostate cancer
The rationale in screening for prostate carcinoma is based on the premise that untreated disease may progress and cause death and that early detection followed by treatment will prevent or delay these events. As PSA is currently the best non-invasive test for prostate cancer and is relatively easy and cheap to measure, it has been widely investigated as a screening test for early disease. 17 Although the studies published to date are mostly small-scale and nonrandomized, a number of conclusions have emerged regarding PSA as a screening test. 17 . Screening healthy men for prostate cancer has been shown to be feasible and practicable. . As a screening test for prostate cancer, PSA has a sensitivity of approximately 71%, a speci¢city of approximately 75% and an average positive predictive value of 37% (at a cut-o¡ point of 4 mg/L). . The vast majority of cancers detected by PSA screening are organ-con¢ned but are likely to progress based on their size and grade.
. Screening for prostate cancer using PSA has the potential to detect malignancy at least 5 years in advance of clinical evidence of disease being present.
The critical question as to whether screening with PSA enhances patient outcome, however, has still not been answered. A clear-cut answer to this question requires a large prospective randomized trial comparing survival in a screened and controlled group. Two such trials are currently in progress, the European Randomized Study of Screening for Prostate Cancer 18 and the Prostate, Lung, Colon and Ovary trial (PLCO) in the US. 18, 19 Both of these trials began in the mid-1990s and currently over 200,000 men have been randomised. 18 Together, these trials have su⁄cient statistical power to detect a 20% di¡erence in prostate cancer mortality between the intervention and control arms. The ¢rst analyses are expected in 2008 and hopefully will provide the evidence to make rational decisions on whether or not to introduce population PSA screening for prostate cancer.
Despite the lack of evidence available at present, certain professional organisations have recommended prostate cancer screening. Thus, the American Cancer Society recommend that both PSA and digital rectal examination (DRE) be o¡ered annually to men with a life expectancy 410 years from age 50, and to men at high risk from age 40. 20 On the other hand, the US Preventative Services Task Force concluded that the available evidence is insu⁄cient to recommend for or against routine screening for prostate cancer using PSA or DRE. 21 In Europe, the EGTM stated that the measurement of PSA can be recommended in symptomatic men if the diagnosis of prostate cancer alters the treatment decision. However, in the absence of data showing that the early detection of prostate cancer does more good than harm, it may be reasonable to restrict PSA testing to asymptomatic men who are prepared to undergo prostate biopsy in the event of an elevated PSA concentration and have a life expectancy of 410 years. 22 CA 125 in monitoring therapy and follow-up in ovarian cancer Standard treatment for patients presenting with advanced ovarian cancer is cytoreductive surgery followed by chemotherapy. 23 For monitoring response to this chemotherapy, multiple studies have shown that serum CA 125 concentrations decrease with tumour regression and increase with progression. 24, 25 For example, Tuxen et al. 25 showed concordance between changes in CA 125 concentrations and the clinical course of disease in 74^95% of cases, based on a review of 15 published studies.
Many de¢nitions of CA 125 response have been suggested 24, 25 but only the de¢nition of Rustin et al. 26 has been validated. According to Rustin et al., 26, 27 response based on CA 125 occurs if concentrations fall by either 50% or 75%. This de¢nition, which was initially derived from a clinical trial comparing maintenance radiotherapy with carboplatin, was subsequently tested in two further studies. 26 Of the 620 patients assessable by CA 125 criteria, only two (0.3%) exhibited a CA 125 response with clinical evidence of progression.
Recently, the 50% and 75% response de¢nitions were compared with clinical criteria for predicting response to a variety of di¡erent drugs undergoing evaluation in phase II trials for relapsed ovarian cancer. 28 In this study, data was available from 25 treatment groups enrolled in 19 phase II clinical trials investigating 14 di¡erent anti-cancer agents.
Overall, there was no signi¢cant di¡erence between response rates obtained by standard and clinical criteria.
These ¢ndings when taken together clearly show that CA 125 is an accurate, convenient (for the patient) and relatively cheap method for assessing response to treatment in patients with ovarian cancer. 29 Following initial chemotherapy for ovarian cancer, many patients are now followed up with serial levels of CA 125. The aim of this longitudinal monitoring is to pre-clinically detect recurrent or metastatic disease, based on the assumption that early administration of salvage chemotherapy enhances outcome. Following a review of the literature, Tuxen et al. 25 showed that the lead-time between CA 125 increase and clinical progression of disease varied from 1^15 months, the median lead-time being about 3^4 months.
Whether this lead-time positively impacts on patient outcome or quality of life is, however, unclear. In order to address this issue, the Medical Research Council in the UK and the European Organisation for Research and Treatment on Cancer (EORTC) are currently carrying out a randomized trial to ascertain whether administering chemotherapy based on CA 125 elevations enhances survival compared to initiating chemotherapy based on clinical evidence of recurrence. 29 Secondary end-points being addressed in this trial include quality of life and health economics. Until the results of this study are known, there is no established role for regularly monitoring asymptomatic patients with CA 125 following the completion of primary therapy for ovarian cancer. However, should such a patient develop symptoms suggestive of relapse, CA 125 may be measured both to help con¢rm recurrent disease and establish a baseline value for possible further therapy. 29 CA 15-3 in postoperative surveillance and monitoring therapy in patients with breast cancer CA 15-3 or the related marker BR 27.29 are widely used in certain countries in the surveillance of patients following the diagnosis of breast cancer. 30, 31 Following a review of the literature, an ASCO Panel concluded that 67% of 352 patients who had undergone surgery for primary breast cancer had CA 15-3 elevations either before or at the time of recurrence. 8 In 1320 patients without evidence of recurrence at the time of the study, 92% had normal CA 15-3 concentrations.
Although a number of small-scale studies have suggested that early treatment of asymptomatic patients based on a rising CA 15-3 concentrations enhanced outcome, 32^34 these ¢ndings have not been con¢rmed in a high level evidence trial to date. 2 In both 1996 and 2000, therefore, the ASCO Panel was unable to recommend routine use of CA 15-3 in order to pre-clinically detect recurrent disease in patients with a previous diagnosis of breast cancer. 8, 35 The ASCO panel have also addressed the potential value of CA 15-3 for monitoring treatment in patients with advanced breast cancer. Summarising the data from 11 studies, the authors concluded that 66% of patients with chemotherapy-induced disease regression exhibited a decrease in marker concentration, 73% of those with stable disease had no signi¢cant change in marker concentration and 80% with progressive disease displayed increasing concentrations. 8 Although these ¢ndings show relatively good correlations between changes in CA 15-3 concentration and response to therapy, the ASCO panel concluded that 'routine use of CA 15-3 to monitor the course of therapy cannot be recommended'. However, the panel also stated that 'in exceptional circumstances such as the presence of osseous metastasis, which are di⁄cult to evaluate clinically, the marker level may be able to support the clinical estimate of disease status. However, the marker cannot in any situation stand alone to de¢ne response to treatment'. 8, 35 Oestrogen receptor for predicting response to hormone therapy in patients with breast cancer Following surgical removal of breast cancer, two main forms of systemic adjuvant therapy are available (i.e. chemotherapy and hormone therapy). Compared to chemotherapy, the side e¡ects of hormone therapy are relatively mild. Hormone therapy is thus the preferred choice of treatment by most women with breast cancer. However, as only about 30% of breast cancers are hormone-dependent (at least in advanced disease), this type of treatment cannot be given to all patients with breast malignancy. The key to the rational administration of hormone therapy is to have a test that will prospectively predict those patients likely to respond.
In the early 1970s, the ER protein was shown to be present in 50^70% of breast cancers. 35 Using pooled data from eight di¡erent institutions, McGuire et al. 35 showed that approximately 55% of ER-positive women with advanced breast cancers responded to endocrine ablation therapy. In contrast, only 8% of ER-negative tumours regressed with this treatment. 36 Thus in advanced breast cancer ER-positive patients are approximately seven times more likely to respond to hormone therapy than ER-negative patients.
The utility of the ER protein in predicting hormone response in early breast cancer was recently validated using a meta-analysis involving over 37 000 women with operable breast cancer enrolled in 55 randomized trials. 37 All these trials compared tamoxifen versus placebo for the adjuvant treatment of breast cancer. The meta-analysis showed that adjuvant tamoxifen prolonged both disease-free survival and overall survival in patients with ER-rich tumours but had little bene¢t in patients who had ERpoor cancers. 37 Speci¢cally, following the adjuvant treatment of breast cancer with tamoxifen for 5 years, ER-rich tumours were approximately eight times more likely to respond than ER-poor tumours. According to Hayes, 38 for a marker to be considered a strong predictor of therapeutic response, it should have a relative predictive value (RPV) 44. For hormone treatment of breast cancer in both adjuvant and advanced disease settings, the RPV of ER clearly surpasses this value.
Owing to the striking di¡erence in response of steroid receptor-positive and negative breast cancers to hormone therapy, both American (ASCO, NACB) and European (EGTM) Expert Panels have recommended that ER be assayed on all new primary breast cancers. 8, 12, 13, 35, 39 HER-2 in predicting response to therapy in breast cancer HER-2, which is also known as c-erbB-2, is a protooncogene that is over-expressed in 15^30% of invasive breast cancers. 40 Potential uses of tumour tissue levels of HER-2 in breast cancer include prognostic classi¢cation, predicting resistance to both endocrine therapy and cyclophosphamide-methotrexate-5-£uorouracil (CMF)-based chemotherapy, selecting for enhanced response to anthracyclene-based chemotherapy and identifying patients with advanced disease likely to respond to the therapeutic antibody trastuzumab (Herceptin 1 , Genentech, San Fransisco CA, US).
Results from both model systems 41 as well as clinical trials 42, 43 have shown that either ampli¢cation or over-expression of the HER-2 gene is necessary for response to trastuzumab. Consequently, prior to patients receiving trastuzumab, a HER-2 assay must be performed. Currently, the only mandatory requirement for HER-2 assay is in selecting patients with advanced breast cancer for treatment with trastuzumab. The recent ASCO guidelines stated that 'expression of HER-2 ampli¢cation can be used to identify patients for whom Herceptin may be of bene¢t for the treatment of metastatic, recurrent or treatment-refractory unresectable locally advanced breast cancer'. 35 Although HER-2 concetrations are usually determined in tumour tissue, the extracellular domain (ECD) of the proto-oncogene can be shed and released into the circulation. Following a systematic review of the literature, Carney et al. 44 identi¢ed 55 publications that described the measurement of HER-2 ECD in blood. In 24 studies on patients with primary breast cancer HER-2 was elevated in approximately 18% (range 0^38%), while in 45 studies involving patients with metastatic breast cancer, HER-2 was increased in approximately 43% (range 23^80%). Some of the key ¢ndings from the systematic review were as follows:
. Patients with high circulating concentrations of HER-2 had a worse outcome than those with low levels. . Patients with high concentrations of HER-2 appeared to derive less bene¢t from both endocrine therapy and CMF-based chemotherapy. . Serum concentrations of HER-2 were potentially useful in pre-clinically detecting recurrent disease and monitoring therapy in patients with advanced disease.
It should be pointed out that most of the studies analysed in this review contained small numbers of patients and were retrospective in design. Furthermore, it was not clear if the information provided by HER-2 was independent of standard criteria (i.e. if the prognostic data was independent of tumour stage, grade or axillary nodal status), if the predictive information for hormone therapy was independent of ER and the information available from serial levels was independent of CA 5-3. Based on available data, it is di⁄cult to recommend routine clinical use of serum HER-2 at present.
Urokinase plasminogen activator and plasminogen activator inhibitor type 1 in assessing prognosis in patients with breast cancer
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) are two proteins causally involved in cancer invasion and metastasis. Consistent with this role in cancer progression, high levels of both proteins have been shown to predict adverse outcome in patients with breast cancer, including the subgroup of patients with axillary node-negative disease. 45 In 2001, the prognostic value of uPA and PAI-1 was validated in a multicentre prospective randomized trial. 46 In this trial, node-negative breast cancer patients with low levels of uPA and PAI-1 were monitored but received no systemic adjuvant chemotherapy. On the other hand, patients with high levels of uPA and/or PAI-1 were randomized to receive adjuvant chemotherapy or to be observed. After a median follow-up period of 32 months, patients with low levels of both proteins had signi¢cantly better disease-free interval than those with elevated levels. Multivariate analysis showed that the prognostic impact of uPA/PAI-1 was independent of tumour grade, tumour size, surgical treatment of primary cancer and steroid receptor status. To the author's knowledge, uPA and PAI-1 are the ¢rst biological markers to have their clinical value validated using a large randomized prospective trial.
In addition to validation in a randomised prospective trial, the prognostic impact of uPA and PAI-1 in breast cancer has also been con¢rmed using a pooled analysis. 47 The pooled analysis used raw data from 18 di¡erent groups of patients (n ¼ 8377). Consistent with the results from the randomized trial referred to above, uPA and PAI-1 were again found to be independent prognostic factors for breast cancer. Although less potent than axillary nodal status, both uPA and PAI-1 were stronger predictors of patient outcome than tumour size, tumour grade, hormone receptor status or patient age. In the nodenegative patients, uPA and PAI-1 were the strongest predictors of both disease-free interval and overall survival.
The results of the randomized prospective trial and pooled analysis clearly show that uPA and PAI-1 are potent and independent prognostic markers in breast cancer.
Although not yet in routine use, the most immediate bene¢t of these markers is likely to be in selecting the subset of node-negative breast cancer patients who do not need or are unlikely to bene¢t from adjuvant chemotherapy. For example, nodenegative patients with low concentrations of uPA or PAI-1 have a low risk of disease relapse and consequently could avoid the side e¡ects and ¢nancial costs of adjuvant chemotherapy. Thus, in the future, assay of uPA and PAI-1 could be used to individualize adjuvant treatment for node-negative breast cancer patients.
Conclusion
From the data presented above, it is clear that in certain situations tumour markers play an important role in the management of patients with cancer. Indeed, in some situations, markers can be used as the sole criterion for clinical decision-making. Examples of this include the use of ER in predicting hormoneresponsiveness in breast cancer; tissue concentrations of HER-2 for selecting patients with advanced breast cancer for treatment with trastuzumab; hCG in monitoring patients with trophoblastic disease; hCG and AFP in the surveillance of patients with diagnosed NSGCT; and CA 125 in monitoring therapy response in patients with ovarian cancer. In other situations, however, the value of markers is less clear, for example the role of PSA in screening for prostate cancer and the measurement of CA 15-3 in the surveillance of patients following the diagnosis of breast cancer.
In recent years, a number of promising new tumour markers have been described. These include mammaglobin for breast cancer, 48 OVX1 for ovarian cancer, 49 survivin for bladder cancer 50 and DD3 PCA3 for prostate cancer. 51 It is important that simple, robust and standardized assays are developed for these analytes, that these assays are rigorously evaluated with respect to technical performance, and that their clinical value is con¢rmed in a level 1 evidence study.
